Profile data is unavailable for this security.
About the company
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
- Revenue in MXN (TTM)18.19bn
- Net income in MXN1.72bn
- Incorporated1996
- Employees1.71k
- LocationGenomma Lab Internacional SAB de CVEdificio SamaraAntonio Dovali Jaime no. 70 Piso 2Colonia Santa FeALVARO OBREGON 01210MexicoMEX
- Phone+52 5 550810000
- Fax+52 5 550810000
- Websitehttps://www.genommalab.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Industri Jamu dn Frms Sd Mncl Tbk PT | 4.12bn | 1.24bn | 16.12bn | 3.56k | 12.92 | 4.54 | 11.90 | 3.92 | 40.62 | 40.62 | 134.92 | 115.65 | 1.05 | 3.17 | 5.99 | 1,128,331,000.00 | 31.51 | 27.62 | 33.97 | 31.69 | 58.69 | 56.70 | 30.13 | 28.98 | 5.29 | -- | 0.0005 | 97.08 | 9.90 | 5.02 | 23.18 | 7.71 | -19.12 | 9.91 |
| Beijing Tong Ren Tang Chinese Medicine | 3.78bn | 1.14bn | 16.39bn | 789.00 | 14.39 | 1.84 | 11.81 | 4.34 | 0.6157 | 0.6157 | 2.04 | 4.81 | 0.3878 | 0.4134 | 4.92 | 2,185,246.00 | 12.14 | 15.34 | 13.34 | 17.17 | 63.00 | 68.94 | 31.29 | 39.16 | 11.43 | -- | 0.0327 | 52.52 | 5.69 | 2.38 | -7.42 | -2.09 | 20.50 | 8.76 |
| Procter & Gamble Health Ltd | 2.45bn | 584.60m | 16.42bn | 1.33k | 28.11 | 13.90 | 26.17 | 6.71 | 184.66 | 184.66 | 772.89 | 373.35 | -- | -- | -- | 9,686,425.00 | -- | -- | -- | -- | 73.77 | -- | 23.89 | -- | 2.30 | 754.85 | 0.0099 | -- | -- | -- | -- | -- | -- | -- |
| CStone Pharmaceuticals | 503.87m | -938.33m | 16.57bn | 93.00 | -- | 19.54 | -- | 32.88 | -0.3259 | -0.3259 | 0.176 | 0.26 | 0.1487 | 1.38 | 1.68 | 1,689,365.00 | -27.69 | -39.13 | -54.45 | -60.19 | -12.18 | 66.69 | -186.23 | -170.86 | 1.20 | -29.83 | 0.554 | -- | -12.21 | -- | 75.16 | -- | -- | -- |
| Genomma Lab Internacional SAB de CV | 18.19bn | 1.72bn | 16.58bn | 1.71k | 9.86 | 1.49 | 7.82 | 0.9114 | 1.71 | 1.15 | 18.06 | 11.27 | 0.7721 | 3.09 | 3.71 | 11,333,190.00 | 7.28 | 6.85 | 10.26 | 10.26 | 63.30 | 61.94 | 9.43 | 8.93 | 1.54 | 3.88 | 0.4025 | 24.81 | 12.99 | 7.92 | 92.74 | 22.77 | 1.53 | -- |
| Viyash Scientific Ltd | 3.16bn | 79.66m | 16.75bn | 1.24k | 123.36 | 6.24 | 74.69 | 5.30 | 1.63 | 1.63 | 64.36 | 32.32 | 1.01 | 2.18 | 4.34 | 13,327,330.00 | 3.29 | 0.4014 | 5.01 | 0.6553 | 48.74 | 42.16 | 3.26 | 0.4199 | 1.08 | 2.25 | 0.3561 | 995.91 | 13.26 | 5.64 | 160.99 | -20.73 | -0.126 | -- |
| Jeena Sikho Lifecare Ltd | 1.18bn | 293.23m | 16.87bn | 3.76k | 57.60 | 25.04 | 49.72 | 14.30 | 12.37 | 12.37 | 49.75 | 28.45 | 1.53 | 4.18 | 7.99 | 1,644,723.00 | 37.92 | 32.29 | 46.06 | 40.74 | 91.31 | 92.07 | 24.86 | 16.78 | 2.14 | 33.36 | 0.231 | -- | 44.59 | 37.80 | 31.10 | 73.77 | 47.62 | -- |
| Phathom Pharmaceuticals Inc | 2.54bn | -4.74bn | 16.92bn | 427.00 | -- | -- | -- | 6.66 | -3.81 | -3.81 | 2.04 | -5.95 | 0.4693 | 5.58 | 3.83 | 344,707.30 | -87.53 | -72.89 | -117.10 | -84.11 | 87.25 | -- | -186.53 | -1,799.61 | 2.19 | -3.35 | 3.68 | -- | 8,001.47 | -- | -65.84 | -- | 0.4505 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Nov 2025 | 39.21m | 3.92% |
| Swedbank Robur Fonder ABas of 30 Dec 2025 | 33.94m | 3.39% |
| Invesco Asset Management Ltd.as of 31 Dec 2025 | 33.30m | 3.33% |
| Skagen ASas of 30 Nov 2025 | 30.67m | 3.07% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 27.92m | 2.79% |
| BlackRock M�xico SA de CV Asesor en Inversiones Independienteas of 08 Jan 2026 | 22.97m | 2.30% |
| BlackRock Fund Advisorsas of 09 Jan 2026 | 22.23m | 2.22% |
| Wellington Management Co. LLPas of 31 Dec 2025 | 20.14m | 2.01% |
| North of South Capital LLPas of 31 Dec 2025 | 15.57m | 1.56% |
| LarrainVial Asset Management AGF SAas of 31 Dec 2024 | 15.37m | 1.54% |
